Carlo Capobianco

Pharma’s external manufacturing landscape is undergoing rapid change. Networks are being redesigned for greater agility, transparency, and resilience — and CMOs are increasingly expected to operate as strategic partners rather than transactional suppliers.

This combined session offers a concise overview of how supplier networks are transforming, what capabilities are emerging, and how these shifts create new opportunities for CMOs in areas such as quality, technical engagement, and long-term collaboration.

The second half of the session is fully interactive, inviting participants from across the industry to exchange experiences, discuss lessons learned, and jointly explore where the external manufacturing model is heading.

Participants will leave with:

• B A shared view on the key drivers shaping the future of external manufacturing
• Insights into how network transformation unlocks new value for CMOs and pharma partners
• A co-created set of principles and expectations that could form the next industry benchmark